| Summary of royalty and commercial payment receivable and contingent consideration activities |
The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the three months ended March 31, 2026 (in thousands): | | | | | | | | | | | | | Balance as of January 1, 2026 | | | Receipt of Royalty and Commercial Payments | | | Balance as of March 31, 2026 | Twist | | $ | 15,000 | | $ | — | | $ | 15,000 | Daré (XACIATO) | | | 21,993 | | | (2) | | | 21,991 | Palobiofarma | | | 10,000 | | | — | | | 10,000 | Kuros | | | 4,500 | | | — | | | 4,500 | Castle Creek | | | 4,395 | | | — | | | 4,395 | Total | | $ | 55,888 | | $ | (2) | | $ | 55,886 |
The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the three months ended March 31, 2025 (in thousands): | | | | | | | | | | | | | | | | Balance as of January 1, 2025 | | | Acquisition of Royalty and Commercial Payment Receivables | | | Receipt of Royalty and Commercial Payments | | | Balance as of March 31, 2025 | Twist | | $ | 15,000 | | $ | — | | $ | — | | $ | 15,000 | Daré (XACIATO) | | | 21,999 | | | — | | | (2) | | | 21,997 | LadRx (MIPLYFFA) | | | 4,850 | | | — | | | (413) | | | 4,437 | Palobiofarma | | | 10,000 | | | — | | | — | | | 10,000 | Kuros | | | 4,500 | | | — | | | — | | | 4,500 | Castle Creek | | | — | | | 4,395 | | | — | | | 4,395 | Total | | $ | 56,349 | | $ | 4,395 | | $ | (415) | | $ | 60,329 |
The following table summarizes the royalty and commercial payment receivable activities under the EIR method during the three months ended March 31, 2026 (in thousands): | | | | | | | | | | | | | | | Balance as of January 1, 2026 | | Income from Purchased Receivables Under the EIR Method | | Receipt of Royalty and Commercial Payments | | | Balance as of March 31, 2026 | Affitech (VABYSMO) | | $ | 17,555 | | $ | 6,696 | | $ | (11,945) | | $ | 12,306 | LadRx (MIPLYFFA) | | | 3,765 | | | 2,297 | | | (1,069) | | | 4,993 | Aptevo (IXINITY) | | | 5,893 | | | 246 | | | (479) | | | 5,660 | Total | | $ | 27,213 | | $ | 9,239 | | $ | (13,493) | | $ | 22,959 |
The following table summarizes the royalty and commercial payment receivable activities under the EIR method during three months ended March 31, 2025 (in thousands): | | | | | | | | | | | | | | | | | | | Balance as of January 1, 2025 | | | Income from Purchased Receivables Under the EIR Method | | | Receipt of Royalty and Commercial Payments | | | Payment of Sales-Based Milestone | | | Balance as of March 31, 2025 | Affitech (VABYSMO) | | $ | 13,105 | | $ | 5,817 | | $ | (11,145) | | $ | 3,000 | | $ | 10,777 | Aptevo (IXINITY) | | | 6,628 | | | 253 | | | (561) | | | — | | | 6,320 | Total | | $ | 19,733 | | $ | 6,070 | | $ | (11,706) | | $ | 3,000 | | $ | 17,097 |
|
| Summary of income from purchased receivables under the cost recovery method and EIR method |
The following table summarizes income recognized from purchased receivables under the EIR method and cost recovery method during the three months ended March 31, 2026 and 2025 (in thousands): | | | | | | | | | Three Months Ended March 31, | | | 2026 | | 2025 | Affitech (VABYSMO) | | $ | 6,696 | | $ | 5,817 | LadRx (MIPLYFFA) | | | 2,297 | | | — | Aptevo (IXINITY) | | | 246 | | | 253 | Total income from purchased receivables under the EIR method | | $ | 9,239 | | $ | 6,070 | | | | | | | | Viracta (OJEMDA) | | $ | 2,769 | | $ | 5,525 | Total income from purchased receivables under the cost recovery method | | $ | 2,769 | | $ | 5,525 |
|